Dietary management of the metabolic syndrome beyond macronutrients

Nutrition Reviews

Volumn 66, Issue 8, 2008, Pages 429-444

  Minich, Deanna M ^a   Bland, Jeffrey S ^a  

^a MetaProteomics LLC   (United States)

Author keywords

Insulin signaling; Mediterranean diet; Metabolic syndrome; Phytochemicals; Protein kinases

Indexed keywords

BERBERINE; CINNAMON EXTRACT; DIHYDROCAFFEIC ACID; EPIGALLOCATECHIN GALLATE; GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE RE; GINSENOSIDE RG 2; GINSENOSIDE RH 2; GREEN TEA EXTRACT; HUMULON; HYDROXYTYROSOL; INSULIN; INSULIN RECEPTOR; ISOFLAVONE DERIVATIVE; METFORMIN; MEVINOLIN; MOMORDICA CHARANTIA EXTRACT; MYRICETIN; OLEUROPEIN; OLIVE OIL; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOSTEROL; PLACEBO; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; QUERCETIN; RESVERATROL; TYROSOL;

ALMOND; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CINNAMON; CLINICAL TRIAL; COMORBIDITY; COPTIS; DIETARY REFERENCE INTAKE; FRUIT; GINSENG; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; HUMULUS LUPULUS; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MACRONUTRIENT; MEDITERRANEAN DIET; METABOLIC SYNDROME X; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYTOCHEMISTRY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TEA; TRIACYLGLYCEROL BLOOD LEVEL; VEGETABLE;

CINNAMOMUM ZEYLANICUM; DIET, MEDITERRANEAN; DIETARY CARBOHYDRATES; FEMALE; GLYCEMIC INDEX; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; PHYTOTHERAPY; SIGNAL TRANSDUCTION; SOY FOODS; TEA;

EID: 48349091804     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2008.00075.x     Document Type: Review

References (183)

1. Sullivan VK. Prevention and treatment of the metabolic syndrome with lifestyle intervention: where do we start? J Am Diet Assoc. 2006 106 : 668 671.
2. Fitch K, Pyenson B, Iwasaki K. Metabolic syndrome and employer sponsored medical benefits: an actuarial analysis. Value Health. 2007 10 (Suppl S21 S28.
3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Executive summary. Cardiol Rev. 2005 13 : 322 327.
4. Pi-Sunyer FX. Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. Obesity (Silver Spring). 2006 14 (Suppl 3 S135 S142.
5. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005 142 : 611 619.
6. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 346 : 393 403.
7. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006 368 : 1673 1679.
8. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007 86 : 285 300.
9. Muzio F, Mondazzi L, Harris WS, et al. Effects of moderate variations in the macronutrient content of the diet on cardiovascular disease risk factors in obese patients with the metabolic syndrome. Am J Clin Nutr. 2007 86 : 946 951.
10. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006 114 : 82 96.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 106 : 3143 3421.
12. Ordovas JM, Kaput J, Corella D. Nutrition in the genomics era: cardiovascular disease risk and the Mediterranean diet. Mol Nutr Food Res. 2007 51 : 1293 1299.
13. Knopp RH, Fish B, Dowdy A, et al. A moderate-fat diet for combined hyperlipidemia and metabolic syndrome. Curr Atheroscler Rep. 2006 8 : 492 500.
14. Lukaczer D, Liska DJ, Lerman RH, et al. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition. 2006 22 : 104 113.
15. Forsythe CE, Phinney SD, Fernandez ML, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids. 2008 43 : 65 77.
16. Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab. 2007 32 : 46 60.
17. Dreon DM, Fernstrom HA, Williams PT, et al. A very low-fat diet is not associated with improved lipoprotein profiles in men with a predominance of large, low-density lipoproteins. Am J Clin Nutr. 1999 69 : 411 418.
18. Krauss RM, Dreon DM. Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. Am J Clin Nutr. 1995 62 (Suppl S478 S487.
19. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr. 2005 25 : 391 406.
20. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000 102 : 2284 2299.
21. Brinkworth GD, Noakes M, Keogh JB, et al. Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. Int J Obes Relat Metab Disord. 2004 28 : 661 670.
22. Farnsworth E, Luscombe ND, Noakes M, et al. Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am J Clin Nutr. 2003 78 : 31 39.
23. Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA. 1994 271 : 1421 1428.
24. Piatti PM, Monti F, Fermo I, et al. Hypocaloric high-protein diet improves glucose oxidation and spares lean body mass: comparison to hypocaloric high-carbohydrate diet. Metabolism. 1994 43 : 1481 1487.
25. Sargrad KR, Homko C, Mozzoli M, et al. Effect of high protein vs high carbohydrate intake on insulin sensitivity, body weight, hemoglobin A1c, and blood pressure in patients with type 2 diabetes mellitus. J Am Diet Assoc. 2005 105 : 573 580.
26. Merchant AT, Kelemen LE, de Koning L, et al. Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis. Am J Clin Nutr. 2008 87 : 168 174.
27. Ebbesson SO, Tejero ME, Nobmann ED, et al. Fatty acid consumption and metabolic syndrome components: The GOCADAN study. J Cardiometab Syndr. 2007 2 : 244 249.
28. Kallio P, Kolehmainen M, Laaksonen DE, et al. Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENUT Study. Am J Clin Nutr. 2007 85 : 1417 1427.
29. Bjorntorp P, Rosmond R. The metabolic syndrome - a neuroendocrine disorder Br J Nutr. 2000 83 (Suppl 1 S49 S57.
30. Salsberg SL, Ludwig DS. Putting your genes on a diet: the molecular effects of carbohydrate. Am J Clin Nutr. 2007 85 : 1169 1170.
31. Monro JA, Shaw M. Glycemic impact, glycemic glucose equivalents, glycemic index, and glycemic load: definitions, distinctions, and implications. Am J Clin Nutr. 2008 87 (Suppl S237 S243.
32. Wolever TM, Jenkins DJ, Jenkins AL, et al. The glycemic index: methodology and clinical implications. Am J Clin Nutr. 1991 54 : 846 854.
33. Venn BJ, Green TJ. Glycemic index and glycemic load: measurement issues and their effect on diet-disease relationships. Eur J Clin Nutr. 2007 61 (Suppl 1 S122 S131.
34. Riccardi G, Rivellese AA, Giacco R. Role of glycemic index and glycemic load in the healthy state, in prediabetes, and in diabetes. Am J Clin Nutr. 2008 87 (Suppl S269 S274.
35. Livesey G, Taylor R, Hulshof T, et al. Glycemic response and health - a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. Am J Clin Nutr. 2008 87 (Suppl S258 S268.
36. Livesey G, Taylor R, Hulshof T, et al. Glycemic response and health - a systematic review and meta-analysis: the database, study characteristics, and macronutrient intakes. Am J Clin Nutr. 2008 87 (Suppl S223 S236.
37. Qi L, Hu FB. Dietary glycemic load, whole grains, and systemic inflammation in diabetes: the epidemiological evidence. Curr Opin Lipidol. 2007 18 : 3 8.
38. Augustin LS, Franceschi S, Jenkins DJ, et al. Glycemic index in chronic disease: a review. Eur J Clin Nutr. 2002 56 : 1049 1071.
39. Panagiotakos DB, Pitsavos C, Skoumas Y, et al. The association between food patterns and the metabolic syndrome using principal components analysis: The ATTICA Study. J Am Diet Assoc. 2007 107 : 979 987.
40. Esmaillzadeh A, Kimiagar M, Mehrabi Y, et al. Dietary patterns, insulin resistance, and prevalence of the metabolic syndrome in women. Am J Clin Nutr. 2007 85 : 910 918.
41. Baxter AJ, Coyne T, McClintock C. Dietary patterns and metabolic syndrome - a review of epidemiologic evidence. Asia Pac J Clin Nutr. 2006 15 : 134 142.
42. Sonnenberg L, Pencina M, Kimokoti R, et al. Dietary patterns and the metabolic syndrome in obese and non-obese Framingham women. Obes Res. 2005 13 : 153 162.
43. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002 288 : 2569 2578.
44. Bazzano LA. The high cost of not consuming fruits and vegetables. J Am Diet Assoc. 2006 106 : 1364 1368.
45. Williams DE, Wareham NJ, Cox BD, et al. Frequent salad vegetable consumption is associated with a reduction in the risk of diabetes mellitus. J Clin Epidemiol. 1999 52 : 329 335.
46. Esmaillzadeh A, Kimiagar M, Mehrabi Y, et al. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr. 2006 84 : 1489 1497.
47. Craig WJ. Phytochemicals: guardians of our health. J Am Diet Assoc. 1997 97 (Suppl S199 S204.
48. Blanck HM, Gillespie C, Kimmons JE, et al. Trends in fruit and vegetable consumption among U.S. men and women, 1994-2005. Prev Chronic Dis. 2008 5 : A35.
49. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev. 2006 64 (Suppl S27 S47.
50. Lairon D. Intervention studies on Mediterranean diet and cardiovascular risk. Mol Nutr Food Res. 2007 51 : 1209 1214.
51. Esposito K, Ciotola M, Giugliano D. Mediterranean diet and the metabolic syndrome. Mol Nutr Food Res. 2007 51 : 1268 1274.
52. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves sexual function in women with the metabolic syndrome. Int J Impot Res. 2007 19 : 486 491.
53. Soriguer F, Rojo-Martinez G, de Fonseca FR, et al. Obesity and the metabolic syndrome in Mediterranean countries: a hypothesis related to olive oil. Mol Nutr Food Res. 2007 51 : 1260 1267.
54. Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, et al. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care. 2007 30 : 2957 2959.
55. Alvarez Leon EE, Henriquez P, Serra-Majem L. Mediterranean diet and metabolic syndrome: a cross-sectional study in the Canary Islands. Public Health Nutr. 2006 9 : 1089 1098.
56. Esposito K, Ciotola M, Giugliano D. Mediterranean diet, endothelial function and vascular inflammatory markers. Public Health Nutr. 2006 9 : 1073 1076.
57. Giugliano D, Esposito K. Is the whole-diet approach better than a low-fat diet in cardiovascular risk reduction? Am J Clin Nutr. 2006 83 : 921 author reply 921-922.
58. Meydani M. A Mediterranean-style diet and metabolic syndrome. Nutr Rev. 2005 63 : 312 314.
59. Bautista MC, Engler MM. The Mediterranean diet: is it cardioprotective? Prog Cardiovasc Nurs. 2005 20 : 70 76.
60. Panagiotakos DB, Polychronopoulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis. 2005 4 : 7.
61. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J. 2004 147 : 106 112.
62. Pitsavos C, Panagiotakos DB, Chrysohoou C, et al. The adoption of Mediterranean diet attenuates the development of acute coronary syndromes in people with the metabolic syndrome. Nutr J. 2003 2 : 1.
63. Fito M, Guxens M, Corella D, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med. 2007 167 : 1195 1203.
64. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004 292 : 1433 1439.
65. Psaltopoulou T, Naska A, Orfanos P, et al. Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 2004 80 : 1012 1018.
66. Waterman E, Lockwood B. Active components and clinical applications of olive oil. Altern Med Rev. 2007 12 : 331 342.
67. Paniagua JA, de la Sacristana AG, Sanchez E, et al. A MUFA-rich diet improves postprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr. 2007 26 : 434 444.
68. Tierney AC, Roche HM. The potential role of olive oil-derived MUFA in insulin sensitivity. Mol Nutr Food Res. 2007 51 : 1235 1248.
69. Perez-Jimenez F, Ruano J, Perez-Martinez P, et al. The influence of olive oil on human health: not a question of fat alone. Mol Nutr Food Res. 2007 51 : 1199 1208.
70. Covas MI, Nyyssonen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 145 : 333 341.
71. Trichopoulou A, Dilis V. Olive oil and longevity. Mol Nutr Food Res. 2007 51 : 1275 1278.
72. Bendini A, Cerretani L, Carrasco-Pancorbo A, et al. Phenolic molecules in virgin olive oils: a survey of their sensory properties, health effects, antioxidant activity and analytical methods. An overview of the last decade. Molecules. 2007 12 : 1679 1719.
73. Perona JS, Vogler O, Sanchez-Dominguez JM, et al. Consumption of virgin olive oil influences membrane lipid composition and regulates intracellular signaling in elderly adults with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2007 62 : 256 263.
74. Fickova M, Hubert P, Klimes I, et al. Dietary fish oil and olive oil improve the liver insulin receptor tyrosine kinase activity in high sucrose fed rats. Endocr Regul. 1994 28 : 187 197.
75. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005 111 : 1448 1454.
76. Iwasaki Y, Kambayashi M, Asai M, et al. High glucose alone, as well as in combination with proinflammatory cytokines, stimulates nuclear factor kappa-B-mediated transcription in hepatocytes in vitro. J Diabetes Complications. 2007 21 : 56 62.
77. Brunelleschi S, Bardelli C, Amoruso A, et al. Minor polar compounds extra-virgin olive oil extract (MPC-OOE) inhibits NF-kappaB translocation in human monocyte/macrophages. Pharmacol Res. 2007 56 : 542 549.
78. Perez-Martinez P, Lopez-Miranda J, Blanco-Colio L, et al. The chronic intake of a Mediterranean diet enriched in virgin olive oil, decreases nuclear transcription factor kappaB activation in peripheral blood mononuclear cells from healthy men. Atherosclerosis. 2007 194 : e141 146.
79. Bellido C, Lopez-Miranda J, Blanco-Colio LM, et al. Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in periphera l blood mononuclear cells from healthy men. Am J Clin Nutr. 2004 80 : 1487 1491.
80. Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J. 2007 28 : 1683 1693.
81. Frojdo S, Cozzone D, Vidal H, et al. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J. 2007 406 : 511 518.
82. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J. 2006 397 : 519 527.
83. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006 444 : 337 342.
84. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006 5 : 493 506.
85. Stefani M, Markus MA, Lin RC, et al. The effect of resveratrol on a cell model of human aging. Ann N Y Acad Sci. 2007 1114 : 407 418.
86. Strobel P, Allard C, Perez-Acle T, et al. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem J. 2005 386 : 471 478.
87. Matter WF, Brown RF, Vlahos CJ. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun. 1992 186 : 624 631.
88. Agullo G, Gamet-Payrastre L, Manenti S, et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol. 1997 53 : 1649 1657.
89. Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000 6 : 909 919.
90. Williams RJ, Spencer JP, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med. 2004 36 : 838 849.
91. Gamet-Payrastre L, Manenti S, Gratacap MP, et al. Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol. 1999 32 : 279 286.
92. Gulati N, Laudet B, Zohrabian VM, et al. The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res. 2006 26 : 1177 1181.
93. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003 290 : 502 510.
94. Merritt JC. Metabolic syndrome: soybean foods and serum lipids. J Natl Med Assoc. 2004 96 : 1032 1041.
95. Azadbakht L, Kimiagar M, Mehrabi Y, et al. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. Am J Clin Nutr. 2007 85 : 735 741.
96. Azadbakht L, Kimiagar M, Mehrabi Y, et al. Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes Care. 2007 30 : 967 973.
97. Noriega-Lopez L, Tovar AR, Gonzalez-Granillo M, et al. Pancreatic insulin secretion in rats fed a soy protein high fat diet depends on the interaction between the amino acid pattern and isoflavones. J Biol Chem. 2007 282 : 20657 20666.
98. Rimbach G, Boesch-Saadatmandi C, Frank J, et al. Dietary isoflavones in the prevention of cardiovascular disease - A molecular perspective. Food Chem Toxicol. 2008 46 : 1308 1319.
99. Decker EA. The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants. Nutr Rev. 1995 53 : 49 58.
100. Walsh MC, Brennan L, Pujos-Guillot E, et al. Influence of acute phytochemical intake on human urinary metabolomic profiles. Am J Clin Nutr. 2007 86 : 1687 1693.
101. Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr. 2003 78 (Suppl S517 S520.
102. Cassidy A, Dalais F. Phytochemicals. In : Gibney MJ, Macdonald IA, Roche HM, eds. Nutrition and Metabolism. Oxford, UK : Blackwell Science 2003 : 307 317.
103. Esposito K, Nappo F, Giugliano F, et al. Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. Am J Clin Nutr. 2003 77 : 139 143.
104. Jacobs DR, Jr., Tapsell LC. Food, not nutrients, is the fundamental unit in nutrition. Nutr Rev. 2007 65 : 439 450.
105. Lila MA. From beans to berries and beyond: teamwork between plant chemicals for protection of optimal human health. Ann N Y Acad Sci. 2007 1114 : 372 380.
106. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006 17 : 4 12.
107. Muniyappa R, Quon MJ. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care. 2007 10 : 523 530.
108. Nawrocki AR, Scherer PE. The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol. 2004 4 : 281 289.
109. Sell H, Dietze-Schroeder D, Eckel J. The adipocyte-myocyte axis in insulin resistance. Trends Endocrinol Metab. 2006 17 : 416 422.
110. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002 51 : 7 18.
111. Slawik M, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev. 2006 5 : 144 164.
112. Patiag D, Gray S, Idris I, et al. Effects of tumour necrosis factor-alpha and inhibition of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci (Lond). 2000 99 : 303 307.
113. Plomgaard P, Bouzakri K, Krogh-Madsen R, et al. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005 54 : 2939 2945.
114. Ranganathan S, Davidson MB. Effect of tumor necrosis factor-alpha on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. Metabolism. 1996 45 : 1089 1094.
115. Schinner S, Scherbaum WA, Bornstein SR, et al. Molecular mechanisms of insulin resistance. Diabet Med. 2005 22 : 674 682.
116. Carlson CJ, White MF, Rondinone CM. Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem Biophys Res Commun. 2004 316 : 533 539.
117. Bullock WH, Magnuson SR, Choi S, et al. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem. 2002 2 : 915 938.
118. Smith U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance - is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord. 2002 26 : 897 904.
119. Solomon TP, Blannin AK. Effects of short-term cinnamon ingestion on in vivo glucose tolerance. Diabetes Obes Metab. 2007 9 : 895 901.
120. Hlebowicz J, Darwiche G, Bjorgell O, et al. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr. 2007 85 : 1552 1556.
121. Pham AQ, Kourlas H, Pham DQ. Cinnamon supplementation in patients with type 2 diabetes mellitus. Pharmacotherapy. 2007 27 : 595 599.
122. Blevins SM, Leyva MJ, Brown J, et al. Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes. Diabetes Care. 2007 30 : 2236 2237.
123. Wang JG, Anderson RA, Graham GM, 3rd., et al. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril. 2007 88 : 240 243.
124. Suppapitiporn S, Kanpaksi N, Suppapitiporn S. The effect of cinnamon cassia powder in type 2 diabetes mellitus. J Med Assoc Thai. 2006 89 (Suppl 3 S200 S205.
125. Baker WL, Gutierrez-Williams G, White CM, et al. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 2008 31 : 41 43.
126. Altschuler JA, Casella SJ, MacKenzie TA, et al. The effect of cinnamon on A1C among adolescents with type 1 diabetes. Diabetes Care. 2007 30 : 813 816.
127. Khan A, Bryden NA, Polansky MM, et al. Insulin potentiating factor and chromium content of selected foods and spices. Biol Trace Elem Res. 1990 24 : 183 188.
128. Qin B, Nagasaki M, Ren M, et al. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract. 2003 62 : 139 148.
129. Imparl-Radosevich J, Deas S, Polansky MM, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Horm Res. 1998 50 : 177 182.
130. Jarvill-Taylor KJ, Anderson RA, Graves DJ. A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. J Am Coll Nutr. 2001 20 : 327 336.
131. Kim DH, Kim CH, Kim MS, et al. Suppression of age-related inflammatory NF-kappaB activation by cinnamaldehyde. Biogerontology. 2007 8 : 545 554.
132. Cao H, Polansky MM, Anderson RA. Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. Arch Biochem Biophys. 2007 459 : 214 222.
133. Kim W, Khil LY, Clark R, et al. Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4. Diabetologia. 2006 49 : 2437 2448.
134. Qin B, Nagasaki M, Ren M, et al. Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. Horm Metab Res. 2004 36 : 119 125.
135. Shankar S, Ganapathy S, Srivastava RK. Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci. 2007 12 : 4881 4899.
136. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr. 2007 26 (Suppl S373 S388.
137. Wolfram S, Wang Y, Thielecke F. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res. 2006 50 : 176 187.
138. Iso H, Date C, Wakai K, et al. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med. 2006 144 : 554 562.
139. Hill AM, Coates AM, Buckley JD, et al. Can EGCG reduce abdominal fat in obese subjects? J Am Coll Nutr. 2007 26 (Suppl S396 S402.
140. Fukino Y, Ikeda A, Maruyama K, et al. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr. 2007 Epub ahead of print]. doi:10.1038/sj.ejcn.1602806
141. Fukino Y, Shimbo M, Aoki N, et al. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo). 2005 51 : 335 342.
142. Ryu OH, Lee J, Lee KW, et al. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract. 2006 71 : 356 358.
143. Hsu SP, Wu MS, Yang CC, et al. Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines. Am J Clin Nutr. 2007 86 : 1539 1547.
144. Mackenzie T, Leary L, Brooks WB. The effect of an extract of green and black tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. Metabolism. 2007 56 : 1340 1344.
145. Hino A, Adachi H, Enomoto M, et al. Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. Diabetes Res Clin Pract. 2007 76 : 383 389.
146. Moon HS, Lee HG, Choi YJ, et al. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chem Biol Interact. 2007 167 : 85 98.
147. Waltner-Law ME, Wang XL, Law BK, et al. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem. 2002 277 : 34933 34940.
148. Serisier S, Leray V, Poudroux W, et al. Effects of green tea on insulin sensitivity, lipid profile and expression of PPARalpha and PPARgamma and their target genes in obese dogs. Br J Nutr. 2007 : 1 9.
149. Cao H, Hininger-Favier I, Kelly MA, et al. Green tea polyphenol extract regulates the expression of genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet. J Agric Food Chem. 2007 55 : 6372 6378.
150. Chan LL, Chen Q, Go AG, et al. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr. 2005 135 : 2517 2523.
151. Uebanso T, Arai H, Taketani Y, et al. Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo). 2007 53 : 482 488.
152. Krawinkel MB, Keding GB. Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia. Nutr Rev. 2006 64 : 331 337.
153. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm. 2003 60 : 356 359.
154. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, et al. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr. 2008 99 : 806 812.
155. Nerurkar PV, Lee YK, Motosue M, et al. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr. 2008 Mar 5 : 1 9 Epub ahead of print]. doi:10.1017/S0007114508937430
156. Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 2004 25 : 496 502.
157. Gao CR, Zhang JQ, Huang QL Experimental study on berberin raised insulin sensitivity in insulin resistance rat models Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997 17 : 162 164.
158. Ni YX Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research Zhong Xi Yi Jie He Za Zhi. 1988 8 : 711 713, 707.
159. Xie P, Zhou H, Gao Y,. The clinical efficacy of berberine in treatment of type 2 diabetes mellitus. Chin J Clin Healthcare. 2005 8 : 402 403.
160. Wei J, Jiang J, Wang S, Wang Z. Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine. Zhong Xi Yi Jie He Ganbing Za Zhi. 2004 14 : 334 336.
161. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008 doi: 10.1210/jc. 2007 2404
162. Zhou L, Yang Y, Wang X, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism. 2007 56 : 405 412.
163. Kim SH, Shin EJ, Kim ED, et al. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes. Biol Pharm Bull. 2007 30 : 2120 2125.
164. Ko BS, Choi SB, Park SK, et al. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005 28 : 1431 1437.
165. Yi P, Lu FE, Chen G Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear transcription factor-kappaB p65 in 3T3-L1 adipocytes Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 27 : 1099 1104.
166. Yi P, Lu FE, Xu LJ, et al. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World J Gastroenterol. 2008 14 : 876 883.
167. Vuksan V, Sung MK, Sievenpiper JL, et al. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis. 2008 18 : 46 56.
168. Yushu H, Yuzhen C, Zhaoying Y, Peiyin Z. The effect of panax ginseng extract (GS) on insulin and corticosteroid receptors. J Trad Chin Med. 1988 8 : 293 295.
169. Yokozawa T, Kobayashi T, Oura H, et al. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem Pharm Bull (Tokyo). 1985 33 : 869 872.
170. Attele AS, Zhou YP, Xie JT, et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes. 2002 51 : 1851 1858.
171. Lee WK, Kao ST, Liu IM, et al. Ginsenoside Rh2 is one of the active principles of Panax ginseng root to improve insulin sensitivity in fructose-rich chow-fed rats. Horm Metab Res. 2007 39 : 347 354.
172. Lee WK, Kao ST, Liu IM, et al. Increase of insulin secretion by ginsenoside Rh2 to lower plasma glucose in Wistar rats. Clin Exp Pharmacol Physiol. 2006 33 : 27 32.
173. Lai DM, Tu YK, Liu IM, et al. Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med. 2006 72 : 9 13.
174. Zhang Z, Li X, Lv W, et al. Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol. 2008 22 : 186 195.
175. Park MW, Ha J, Chung SH. 20(S)-Ginsenoside Rg3 enhances glucose-stimulated insulin secretion and activates AMPK. Biol Pharm Bull. 2008 31 : 748 751.
176. Yoon SH, Han EJ, Sung JH, et al. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. Biol Pharm Bull. 2007 30 : 2196 2200.
177. Humulus lupus. Monograph. Altern Med Rev. 2003 8 : 190 192.
178. Yajima H, Ikeshima E, Shiraki M, et al. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J Biol Chem. 2004 279 : 33456 33462.
179. Tripp ML, Pacioretty L, Konda VR, Darland G, Emma D, Bland J, Babish, J. Selective kinase response modulators (SKRMS) from Humulus lupulus and Acacia nilotica modulate multiple kinases and improve insulin sensitivity in vitro and in vivo. FASEB J. 2007 21 : A232.1.
180. Bland JS. What role has nutrition been playing in our health? The xenohormesis connection. Integ Med. 2007 6 : 22 24.
181. Grundy SM, Hansen B, Smith SC, Jr., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol. 2004 24 : e19 24.
182. Frame S, Zheleva D. Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin Ther Targets. 2006 10 : 429 444.
183. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001 86 : 972 979.